Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Martine Rothblatt, Chairperson & CEO of United Therapeutics (NASDAQ:UTHR), sold 8,000 shares of common stock for approximately $3.1 million, at prices ranging from $397.226 to $399.3264, according to a Form 4 filing with the Securities and Exchange Commission.
The sales occurred in multiple transactions on September 10 and September 11, 2025. On the same days, Rothblatt also exercised options to acquire 8,000 shares of United Therapeutics stock at a price of $120.26, for a total value of $962080. The company maintains strong fundamentals with an industry-leading gross profit margin of 89%. InvestingPro subscribers can access 13 additional key insights about UTHR’s performance and valuation metrics.
In other recent news, United Therapeutics has reported positive Phase 3 trial results for its Tyvaso drug in treating idiopathic pulmonary fibrosis (IPF). This has led to several investment firms raising their price targets for the company. UBS increased its price target to $560, maintaining a Buy rating, while Cantor Fitzgerald raised its target to $525, also keeping an Overweight rating. H.C. Wainwright adjusted its price target to $500, citing a 75% probability of approval for Tyvaso in IPF and estimating adjusted peak sales of $5.8 billion. Jefferies also raised its price target to $564 after the Tyvaso Phase 3 IPF study met its primary endpoint, showing significant improvement in forced vital capacity compared to placebo. These developments have positioned United Therapeutics favorably in the market, with analysts noting the potential for substantial peak sales. UBS highlighted the unexpected positive outcome of the trial, which surprised many investors and analysts. The overall sentiment from analysts suggests confidence in the future success of Tyvaso in the IPF market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.